Jpmorgan Chase & CO Cytom X Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 105,294 shares of CTMX stock, worth $243,229. This represents 0.0% of its overall portfolio holdings.
Number of Shares
105,294
Previous 811,630
87.03%
Holding current value
$243,229
Previous $835,000
91.98%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CTMX
# of Institutions
67Shares Held
44.9MCall Options Held
8.9KPut Options Held
47.9K-
Tang Capital Management LLC San Diego, CA6.72MShares$15.5 Million0.28% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$12.1 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.12MShares$11.8 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX3.93MShares$9.08 Million0.9% of portfolio
-
Acadian Asset Management LLC Boston, MA3.23MShares$7.47 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $152M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...